Merck has signed a definitive agreement to acquire VelosBio. The $2.75bn deal hinges around VelosBio’s ROR1-targeting antibody therapies, and particularly ADC VLS-101, for both blood and solid cancers. What makes ROR1 a promising target for various oncology indications?
(Reuters) - Merck & Co Inc said on Thursday it agreed to acquire privately held VelosBio for $2.75 billion in cash, in a move that will help it strengthen its cancer drug portfolio.
Biopharmaceutical company VelosBio has dosed the first patient in a Phase II trial of investigational drug VLS-101 in patients with solid tumours.
VelosBio Inc. (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track and Orphan Drug designation for VLS-101 for the treatment of patients with mantle cell lymphoma (MCL). VLS-101 is a ROR1-directed antibody-drug conjugate (ADC) that is currently being studied in a first-in-human Phase 1 clinical trial in patients with relapsed or refractory hematologic cancers.
Market Place
Share Share
Share Share
